Abstract
Introduction Although HPN patients often have concomitant medical conditions, little has been done to assess the role of multi-morbidity in relation to HPN care (1-3). A validated method for determining multi-morbidity in HPN patients could be beneficial in determining the needs and risks for each HPN patient.
We previously studied the effect of a multidisciplinary nutritional support team (MNST) on quality improvement HPN care (QIP-PN) (4). In a secondary analysis, we explored the options for measuring multi-morbidity of patients in the QIP-PN study. In this report, we describe the results of a pilot study on measuring multi-morbidity in HPN patients to determine its value in HPN care.
Objective Determine the role of multi-morbidity scoring in HPN care.
Methods 60 HPN patients (30 study patients and 30 case-matched controls) were reviewed for demographics, CIRS Score, number of PN formula changes, hospitalizations and hospital length of stay. Histograms were produced to visually examine the data and cutoffs were selected for CIRS scores based on this information. A matrix plot was drawn showing Spearman correlations among the three variables of interest. The data was then subjected to Kruskal-Wallis and Wilcoxon Rank Sum Tests and Negative Binomial Regression Models to determine if the groups differed significantly.
Results 28 patients had CIRS scores <17, while 32 patients had CIRS scores ≥17. The results of negative binomial regression indicate that the number of hospitalizations was a significant predictor of total hospital LOS at the 5% alpha level and that the total hospital LOS of patients with a CIRS Score <17 was significantly different from that of patients with a CIRS≥17 at 5% alpha level.
Conclusion We found the CIRS method was well suited to use in HPN patients. It was easy to learn and perform. It provided a single variable which could be used a summary statement of patient multimorbidity. When the CIRS data on 60 long term HPN patients was analyzed, a trend emerged wherein a higher CIRS score was associated with greater hospital LOS. This approach requires greater study and validation.
What is already known on this topic?The risk of HPN complications is known to relate to patient demographics, length of functional bowel, duration of HPN therapy and macronutrient content. A validated method for determining multi-morbidity in HPN patients could be beneficial in determining the needs of and risk for each HPN patient.
What this study adds The study the explores the role of measuring multi-morbidity scoring in HPN care to determine the risk of adverse effects during therapy.
How this study might affect research, practice or policy?The study suggests that using CIRS scoring for HPN patients could help healthcare providers and payors allocate resources based on risk analysis.
Competing Interest Statement
Michael Rothkopf and Michael Saracco are consultants for Amerita, Inc. Rebecca Brown, Jamie Haselhorst, Francine Gagliardotto, Debbie Stevenson, Andrew DePalma are employees of Amerita, Inc.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Western Institutional Review Board: We believe the study is exempt under 45 CFR 46.104(d)(2), because it is a survey and observation study collecting information about improving the quality of the parenteral nutrition program with the possibility of eventually publishing the data.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
